Advanced search: Search from
Select basic information for advanced search
| Free word |
|---|
| Details |  |
|---|---|
| Related links |  |
| Search |  |
Rchr
J-GLOBAL ID：200901034482030386
Update date: Jan. 31, 2024 HATTA Yoshihiro
ハッタ ヨシヒロ | HATTA Yoshihiro
ClipsResearch keywords (6)：
Transfusion
, Transplantation
, Hematopoietic Stem Cell
, Hematologic Malignancy
, Molecular Biology
, Hematologic Oncology
Research theme for competitive and other funds (1)： - 2015 - 2016 AYA世代における急性リンパ性白血病の生物学的特徴と小児型治療法に関する研究
- Two novel high-risk adult B-cell acute lymphoblastic leukemia subtypes with high expression of CDX2 and IDH1/2 mutations. 2022. 139. 12. 1850-1862
- Yoshihiro Hatta. Pirarubicin-based intensive chemotherapy followed by consolidative high-dose chemotherapies for peripheral T-cell lymphomas: A noncomparative phase 2 study. Hematological Oncology. 2022
- Yoshihiro Hatta. Dasatinib-based 2-step induction for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood Advance. 2022. 6. 2. 624-636
- Yoshihiro Hatta. Ideal dose intensity og R-CHOP in diffuse large B-cell lymphoma. Expert Review of Anticancer Therapy. 2022. 22. 6. 583-595
- Hatta Yoshihiro. Clinical impact of central nervous system-directed therapies on intravascular large B-cell lymphoma: A single institution's experience. eJHaem. 2022. 3. 2. 467-470
- 40.小池隆、入山規良、中川優、高橋宏通、濱田高志、内野慶人、三浦勝浩、八田善弘、中山智祥、武井正美. びまん性大細胞型B細胞リンパ腫への形質転換をきたしたCD5陽性節性濾胞辺縁帯リンパ腫. 臨床血液. 2020. 61. 3. 245-250
- Yoshihiro Hatta, Shuichi Mizuta, Keitaro Matsuo, Shigeki Ohtake, Masako Iwanaga, Isamu Sugiura, Noriko Doki, Heiwa Kanamori, Yasunori Ueda, Chikamasa Yoshida, et al. Final analysis of the JALSG Ph+ALL202 study: tyrosine kinase inhibitor-combined chemotherapy for Ph+ALL. Annals of hematology. 2018. 97. 9. 1535-1545
- Shigeyuki Uno, Torahiko Tanaka, Hiroki Ashiba, Makoto Fujimaki, Mutsuo Tanaka, Yoshihiro Hatta, Masami Takei, Koichi Awazu, Makoto Makishima. Sensitive typing of reverse ABO blood groups with a waveguide-mode sensor. Journal of Bioscience and Bioengineering. 2018. 126. 1. 131-137
- 1.Sato E, Iriyama N, Tokuhira M, Takaku T, Ishikawa M, Nakazato T, Sugimoto KJ, Fujita H, Fujioka I, Asou N, et al. Introduction of second-generation tyrosine kinase inhibitors may reduce the prognostic impact of high-risk patients, according to the European treatment and outcome study (EUTOS) score. Leukemia and Lymphoma. 2018. 59. 5. 1105-112
- Naoto Takahashi, Tetsuzo Tauchi, Kunio Kitamura, Koichi Miyamura, Yoshio Saburi, Yoshihiro Hatta, Yasuhiko Miyata, Shinichi Kobayashi, Kensuke Usuki, Itaru Matsumura, et al. Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study. International journal of hematology. 2018. 107. 2. 185-193
- 1336専門家による私の治療 2017-2018年度版
日本医事新報社 2017 ISBN:9784784946501 - 増刊号.白血病学(下)
日本臨床社 2016 - 急性リンパ性白血病(ALL)の基礎と臨床
医薬ジャーナル社 2016 - 血液疾患診療ハンドブック 改訂第3版(分担執筆
医薬ジャーナル社 2015 - 白血病診療Q & A(分担執筆)
中外医学社 2015
-
Dasatinib-Based Two-Step Induction Prior to Allogeneic Hematopoietic Cell Transplantation for Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of the JALSG Ph+ALL213 Study
(American Society of Hematology (ASH) 61th annual meeting 2019) -
TKI時代のフィラデルフィア染色体陽性急性リンパ性白血病(Ph+ALL)治療の進歩
(第57回日本癌治療学会学術集会 2019) -
ELTS scoreは白血病死と分子学的反応を明確に予測する
(第81回日本血液学会総会 2019) -
TKI治療を受けたAYA世代慢性期慢性骨髄性白血病患者の予後解析
(第81回日本血液学会総会 2019) -
喫煙はTKI治療を受けている慢性期CML患者のアウトカムに影響する
(第81回日本血液学会総会 2019)
- - 1983 Nihon University Faculty of Medicine 医学
- 2006/05 - 2023/03 日本大学 医学部
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.
Return to Previous Page
